// App-Quantinova.ai

10516 : Vincristine/irinotecan upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group (COG) AHEP0731 study committee.

Researchers

Presenter

  • Howard M. Katzenstein

Principal Investigators

  • Wayne Lee Furman

  • Marcio Malogolowkin

  • Mark D. Krailo

  • Mary B McCarville

  • Alexander Towbin

  • Greg Tiao

  • Milton Finegold

  • Sarangarajan Ranganathan

  • Stephen Dunn

  • Max Langham

  • Eugene McGahren

  • Carlos Rodriguez-Galindo

  • Rebecka Meyers

Medical Centers

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • St. Jude Children's Research Hospital, Memphis, TN

  • University of California, San Francisco, CA

  • Children's Oncology Group, Monrovia, CA

  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH

  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH

  • Texas Childrens, Houston, TX

  • Children's Hosp of Pittsburgh of UPMC, Pittsburgh, PA

  • Alfred Dupont Children's Hospital, Wilmington, DE

  • UTHSC, Memphis, TN

  • University of Virgina, Charlottesville, VA

  • Dana-Farber Cancer Institute, Children's Hospital, Boston, MA

  • University of Utah, Salt Lake City, UT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hepatoblastoma

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Alfa-fetoprotein

  • Adrucil injection

  • Fluorouracil

  • Vincristine

  • Doxorubicin

  • Irinotecan

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00980460

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved